These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 33591642)
21. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. Li T; Wang J BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954 [TBL] [Abstract][Full Text] [Related]
23. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525 [TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
25. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
26. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Abbott RC; Cross RS; Jenkins MR Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597 [TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552 [TBL] [Abstract][Full Text] [Related]
28. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940 [TBL] [Abstract][Full Text] [Related]
29. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. Yoon DH; Osborn MJ; Tolar J; Kim CJ Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163 [TBL] [Abstract][Full Text] [Related]
30. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594 [TBL] [Abstract][Full Text] [Related]
31. CAR T Cell Therapy for Solid Tumors. Newick K; O'Brien S; Moon E; Albelda SM Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544 [TBL] [Abstract][Full Text] [Related]
32. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Sukari A; Abdallah N; Nagasaka M Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123 [TBL] [Abstract][Full Text] [Related]